Recent biopharma mergers and acquisitions have highlighted a shift where the workforce and talent acquisition are increasingly becoming the central asset rather than just the therapeutic products.
Recent biopharma mergers and acquisitions have highlighted a shift where the workforce and talent acquisition are increasingly becoming the central asset rather than just the therapeutic products.
READ MORE
HeartFlow, a pioneering AI firm specializing in cardiac image analysis, has initiated legal action against rival Cleerly over alleged patent infringements, highlighting the competitive tensions in cardiac AI innovation.
Five of the leading U.S. health systems are transitioning to an emerging category in health IT, demonstrating a significant trend in healthcare technology adoption.
Despite a Phase 3 study where it was outperformed by Sanofi’s Avapro, Travere Therapeutics' Filspari has received FDA approval as the only treatment available for focal segmental glomerulosclerosis.
As the pharma industry steps into the Q1 earnings season, key themes include new revenue streams from oral GLP-1 medicines and ongoing challenges in regulatory and pricing landscapes.
CMS has approved more than 150 digital health companies to participate in its ACCESS chronic care pilot, aiming to advance technology-driven care models with outcome-based payments.
Revolution Medicines announced breakthrough data showing a targeted pill nearly doubled survival in metastatic pancreatic cancer patients compared to chemotherapy.
Regeneron has entered the radiopharmaceutical arena with a strategic alliance valued at up to $4.3 billion with Telix, positioning the company to strengthen its oncology portfolio. Analysts highlight this as a significant move that broadens Regeneron's capabilities in targeted cancer therapies.
AbbVie has made a significant move into the pain medicine sector through a licensing agreement with China’s Haisco valued at up to $715 million. This marks AbbVie’s first foray into novel pain therapies, entering a market currently led by Vertex’s NaV1.8 inhibitor, Journavax.
The FDA’s approach to regulatory flexibility, particularly concerning rare diseases, is evolving, resulting in both opportunities and challenges for biopharma companies.
The FDA’s policy to publish complete response letters (CRLs) has increased transparency surrounding drug approval rejections and encouraged biopharma companies to be more detailed in their disclosures.
